Table 1.
Baseline Characteristics
| Placebo (n=25) | Sildenafil (n=23) | p | |
|---|---|---|---|
| Clinical Characteristics | |||
| Age (years) | 71 (65, 77) | 69 (62, 72) | 0.2 |
| Female (%) | 56 | 61 | 0.7 |
| Body Mass Index (kg/m2) | 31.2 (28.4, 33.3) | 29.9 (27.4, 38.4) | 0.97 |
| NYHA class II/III (%) | 44/56 | 43/57 | 0.97 |
| Hypertension (%) | 84 | 74 | 0.4 |
| Diabetes (%) | 32 | 39 | 0.6 |
| Obese (%) | 64 | 48 | 0.3 |
| Coronary artery disease (%) | 32 | 35 | 0.8 |
| Atrial fibrillation/flutter history (%) | 24 | 30 | 0.6 |
| Exam | |||
| Jugular venous pressure (%) | 0.4 | ||
| < 8 cm | 48 | 61 | |
| 8–12 cm | 28 | 26 | |
| 13–16 cm | 20 | 4 | |
| > 16 cm | 4 | 9 | |
| Peripheral Edema (%) | 0.2 | ||
| None | 40 | 57 | |
| Trace | 44 | 35 | |
| Moderate | 16 | 9 | |
| Severe | 0 | 0 | |
| Laboratories | |||
| Hemoglobin (gm/dL) | 13.3 (12.3, 13.7) | 13.1 (12.4, 14.4) | 0.4 |
| Creatinine (mg/dL) | 1.0 (0.9, 1.1) | 1.0 (0.8, 1.3) | 0.7 |
| NT-proBNP (pg/mL) | 435 (132,618) | 353 (76,788) | 0.5 |
| Medications | |||
| ACEI/ARB (%) | 72 | 61 | 0.4 |
| Beta Blocker (%) | 80 | 74 | 0.6 |
| Diuretic (%) | 68 | 65 | 0.8 |